Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays dropped their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Stock Up 1.0 %

Shares of Cellectis stock opened at $2.00 on Friday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $1.93 and a 200 day moving average price of $2.13. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77. The firm has a market cap of $111.16 million, a P/E ratio of -1.54 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the firm posted ($0.31) earnings per share. On average, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its holdings in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after acquiring an additional 12,467 shares during the period. XTX Topco Ltd acquired a new position in Cellectis during the 2nd quarter valued at about $29,000. Long Focus Capital Management LLC grew its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Finally, First Affirmative Financial Network acquired a new stake in shares of Cellectis in the third quarter valued at approximately $45,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.